Evoke Pharma, Inc. Announces Full Exercise of Underwriters' Over-Allotment Option

Published: Oct 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 315,000 shares of its common stock, at a price to the public of $12.00 per share. The over-allotment option was granted in connection with the Company's previously announced underwritten initial public offering of 2,100,000 shares of common stock. The exercise brings the expected total gross proceeds from the offering to $28,980,000, before underwriting discounts and commissions and estimated offering expenses.

Help employers find you! Check out all the jobs and post your resume.

Back to news